| Morningstar Fund Report | 03/04/2025 |  |
Polar Capital Funds PLC - Polar Capital Healthcare Opportunities Fund Inc |
| Performance History | 31/03/2025 |
| Growth of 1,000 (GBP) | Advanced Graph |
 | Fund | 9.4 | 2.6 | 3.4 | 7.4 | -8.9 |
| +/-Cat | 0.0 | 7.3 | 6.5 | 6.4 | -7.3 |
| +/-B’mrk | -8.8 | -3.2 | 5.9 | 4.7 | -10.8 |
| Category: Sector Equity Healthcare | ||||||
| Category Benchmark: Morningstar Gbl Health TME ... | ||||||
| Key Stats | ||
| NAV 01/04/2025 | USD 45.02 | |
| Day Change | -1.38% | |
| Morningstar Category™ | Sector Equity Healthcare | |
| ISIN | IE00B28YJN35 | |
| Fund Size (Mil) 01/04/2025 | USD 1639.53 | |
| Share Class Size (Mil) 01/04/2025 | USD 15.38 | |
| Max Initial Charge | 5.00% | |
| Ongoing Charge 29/11/2024 | 1.61% | |
| Investment Objective: Polar Capital Funds PLC - Polar Capital Healthcare Opportunities Fund Inc |
| The investment objective of the Fund is to preserve capital and achieve long term capital appreciation. The Fund will seek to achieve its investment objective by investing in a globally diversified portfolio of healthcare companies. The Fund will at all times invest at least two thirds of its total assets (excluding cash) in healthcare-related companies worldwide. The Fund will invest at least 51% of its gross assets on a continuous basis directly in Equity Participations. Subject to the investment restrictions described in Appendix II of the Prospectus, investments will be made in transferable securities including, but not limited to, shares, equity warrants and other types of securities such as preferred shares, which may be listed on a Regulated Market or unlisted, and issued by companies, and Global, American and European depository receipts. The Fund may not invest more than 10% of its Net Asset Value in unlisted securities. |
| Returns | ||||||||||||||||
|
| Management | ||
Manager Name Start Date | ||
Gareth Powell 03/12/2007 | ||
James Douglas 30/09/2015 | ||
Inception Date 03/12/2007 | ||
| Category Benchmark | |
| Fund Benchmark | Morningstar Benchmark |
| MSCI ACWI/Health Care NR EUR | Morningstar Gbl Health TME NR USD |
| Portfolio Profile for Polar Capital Funds PLC - Polar Capital Healthcare Opportunities Fund Inc | 28/02/2025 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||
| Top 5 Holdings | Sector | % |
 Swedish Orphan Biovitrum AB |  Healthcare | 7.59 |
| UCB SA | Healthcare | 7.37 |
| Zealand Pharma AS | Healthcare | 6.65 |
 Novo Nordisk AS Class B | Healthcare | 6.50 |
| argenx SE | Healthcare | 6.13 |
| ||
Increase  Decrease  New since last portfolio | ||
| Polar Capital Funds PLC - Polar Capital Healthcare Opportunities Fund Inc | ||
| Growth Of 1000 (GBP) | 31/03/2025 |
|
| Annual Returns (GBP) | 31/03/2025 | |||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 31/03 | |
| Price Return | 14.30 | 13.79 | 14.53 | 9.45 | 2.63 | 3.37 | 7.36 | -8.89 |
| +/- Category | 11.61 | -3.23 | -2.94 | 0.01 | 7.30 | 6.49 | 6.39 | -7.29 |
| +/- Category Index | - | - | - | -8.77 | -3.17 | 5.90 | 4.66 | -10.82 |
| % Rank in Category | 4 | 75 | 46 | 58 | 27 | 14 | 8 | 94 |
| Trailing Returns (GBP) | 01/04/2025 | ||
| Total Returns | +/- Category | +/- Category Index | |
| 1 Day | -1.38 | -1.42 | -1.17 |
| 1 Week | -5.35 | -2.89 | -4.05 |
| 1 Month | -9.45 | -3.58 | -3.70 |
| 3 Months | -10.14 | -8.31 | -9.60 |
| 6 Months | -15.32 | -9.33 | -10.31 |
| YTD | -10.14 | -8.31 | -10.77 |
| 1 Year | -14.45 | -7.66 | -11.80 |
| 3 Years Annualised | 1.75 | 3.75 | -0.35 |
| 5 Years Annualised | 9.01 | 2.99 | 0.71 |
| 10 Years Annualised | 6.63 | 0.61 | -1.21 |
| Category: Sector Equity Healthcare | |||
| Category Index: Morningstar Gbl Health TME NR USD | |||
| Quarterly Returns (GBP) | 31/03/2025 | |||
| Quarter 1 | Quarter 2 | Quarter 3 | Quarter 4 | |
| 2025 | -8.89 | - | - | - |
| 2024 | 12.14 | 0.30 | 1.07 | -5.56 |
| 2023 | -2.83 | 5.83 | -6.33 | 7.31 |
| 2022 | -4.63 | -4.80 | 11.92 | 1.00 |
| 2021 | -1.23 | 5.76 | 4.51 | 0.25 |
| 2020 | -13.57 | 25.18 | -1.90 | 7.90 |
| Morningstar Rating™(Relative to Category) | 28/02/2025 | ||||||||||||||||||||
| |||||||||||||||||||||
| Category : Sector Equity Healthcare | Click here to see our Methodology | ||||||||||||||||||||
| Volatility Measurements | 31/03/2025 | ||||||||||
| |||||||||||
| Modern Portfolio Statistics | 31/03/2025 | 31/03/2025 |
| Standard Index | Best Fit Index | |
| Morningstar Gbl Health TME NR USD | Morningstar Gbl Health TME NR USD | |
| 3-Yr Beta | 0.93 | 0.91 |
| 3-Yr Alpha | 0.23 | 1.36 |
| Investment Style Details | 28/02/2025 | ||||||||||||||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||
| Category: Sector Equity Healthcare | |||||||||||||||||||||||||||||||||||||||||
| Asset Allocation | 28/02/2025 |
| ||||||||||||||||||||||||||
| World Regions | 28/02/2025 | ||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||
| Category: Sector Equity Healthcare | |||||||||||||||||||||||||||||||||||||||||||
| Sector Weightings | 28/02/2025 | ||||||
| |||||||
| Category: Sector Equity Healthcare | |||||||
| Top 10 Holdings | 28/02/2025 |
| Portfolio NEW | |
| Total Number of Equity Holdings | 36 |
| Total Number of Bond Holdings | 0 |
| Assets in Top 10 Holdings | 53.06 |
| Name | Sector | Country | % of Assets | ||
| Swedish Orphan Biovitrum AB | | Sweden | 7.59 | ||
| UCB SA | | Belgium | 7.37 | ||
| Zealand Pharma AS | | Denmark | 6.65 | ||
| Novo Nordisk AS Class B | | Denmark | 6.50 | ||
| argenx SE | | United States | 6.13 | ||
| Fresenius SE & Co KGaA | | Germany | 4.58 | ||
| Sanofi SA | | France | 3.89 | ||
| Intuitive Surgical Inc | | United States | 3.59 | ||
| H. Lundbeck AS Ordinary Shares - Class B | | Denmark | 3.38 | ||
| Globus Medical Inc Class A | | United States | 3.37 | ||
| Increase Decrease New since last portfolio | |||||
| Category: Sector Equity Healthcare | |||||
| Management | ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
| |
| Biography | |
| Gareth Powell joined Polar Capital in 2007 to establish the healthcare investment team. He is joint manager of the Healthcare Opportunities Fund. He joined Framlington in 1999, later becoming a portfolio manager on the Framlington Health Fund. In 2002, Gareth helped launch the Framlington Biotech Fund, which he managed until his departure. Gareth studied biochemistry at Oxford, during which time he worked at Yamanouchi, a leading Japanese pharmaceutical company (later to become Astellas), as well as various academic laboratories including the Sir William Dunn School of Pathology, the Wolfson Institute for Biomedical Research and Oxford Business School. He is a CFA charterholder. |
|
| Fund Manager | James Douglas |
| Manager Start Date | 30/09/2015 |
| |
| Biography | |
| James joined Polar Capital in September 2015 and is a Fund Manager for the Healthcare team. He was appointed Co-Fund Manager for the Polar Capital Global Healthcare Trust in May 2017.Prior to joining Polar Capital, James worked in equity sales specialising in global healthcare at Morgan Stanley, RBS and HSBC. James also has equity research experience garnered from his time at UBS, where he worked as an analyst in the European pharmaceutical and biotechnology team. Before moving across to the financial sector, he worked as a consultant for EvaluatePharma. James received a PhD and first class honours degree in Medicinal Chemistry from Newcastle University. Further to this, James also holds an ACCA diploma in financial management. |
| Fees and Expenses | ||||||||||||
| ||||||||||||
| Purchase Details | ||||||||
| ||||||||
| ||||||||